FDA Questions Efficacy Of Titan’s Probuphine Ahead Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Some patients still need a prescription for supplemental sublingual tablets, FDA says, which may take away the continuous-release implant’s advantage for treating opioid dependence.